Abstract
Introduction
Breast cancer is the most common malignant tumour, and only second to lung and bronchus cancer as the cause of cancer-related deaths in women, which is often due to the development of metastatic disease 1 . For improving targeted treatments and accurate prognoses of patients with breast cancers, a comprehensive understanding of the mechanism of metastasis is an urgent requirement. Epithelial-mesenchymal transition (EMT), which is known as the probable first step in the complex process of metastasis, is a distinctive morphological change, in which the series of events converting the epithelial cancer cells switch from a well-differentiated, adherent phenotype to an individual, invasive migratory mesenchymal cell 2 . EMT is vital for morphogenesis, such as physiological embryogenesis and histogenesis, and involved in multiple pathological processes, such as wound healing, renal fibrosis and tumour metastasis. EMT is mainly characterised by loss of E-cadherin (CDH1) expression and other special molecular changes that promote architectural changes, followed by the loss of cell-cell junction, cell-matrix adhesion and modulation of polarity, resulting in acquisition of mesenchymal features, such as spindle shape and increased migratory and invasive capacity 2, 3 . On the other hand, EMT is also supposed to be associated with cancer stem cells (CSCs), by generating self-renewing cells, which is contributed to the tumorigenesis and multi-drug resistance 4 .
The aim of this review was to discuss the role of EMT in invasion and metastasis of breast cancers. . Recent research shows that Snail protects the breast cancer cell from hypoxia attack, at least partly via beta-catenin which upregulated expression of HIF-1 dependent genes 10 . Snail interacted with Suv39H1, a major methyltransferase responsible for H3K9me3 that intimately links to DNA methylation, and recruited it to the promoter of E-cadherin for transcriptional repression, and knockdown of Suv39H1 restored E-cadherin expression by blocking H3K9me3 and DNA methylation and the ZEB family (ZEB1 and SIP1) that recognise the E-Box DNA sequence located near the transcriptional initiation site of CDH1, recruiting transcriptional co-factors and histone deacetylases 8 . Snail was the first discovered and expressed in all EMT processes, which can be induced through signalling involved in EMT, including tyrosine and serine/threonine kinase receptor-associated pathways, and Wnt signalling pathways 8 . Besides repression of E-cadherin, Snail also downregulates the expression of other epithelial molecules, and induces Type 3 EMTs occur in epithelial cancer cells, with genetic and epigenetical differences from normal epithelial cells, specifically in genes that favour clonal outgrowth and the development process of localised tumours. The epithelial cancer cells undergo a type 3 EMT and convert to a mesenchymal phenotype, resulting in invasive and metastatic characteristics, and subsequently generate the high malignant, potentially lethal behaviour of cancer progression 3 . Till date, it is still unclear what specific signals trigger type 3 EMT in carcinoma, how and when EMT and MET programmes and the genes involved in these processes are coordinated ( Figure 1 ).
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A hallmark of EMT is losing expression of E-cadherin, which is the key cellcell adhesion molecule and caretaker of the epithelial phenotype 6 . Besides E-cadherin, many other markers are used to distinguish between epithelial and mesenchymal-like phenotypes, such as downregulation of plakoglobin, occluding, α-catenin, claudins 3/4/7, and upregulation of vimentin, fibronectin, ACTA2 2 . Importantly, carcinoma cells may undergo EMTs to different extents and not completely lose their epithelial phenotype during the process, with some cells expressing epithelial and mesenchymal markers simultaneously and other cells becoming completely mesenchymal 6 .
Transcription regulation
It is reported that loss of CDH1 is sufficient to induce EMTs, and sequent invasive and anoikis resistance 7 , indicating the significance of repressors of CDH1 in the trigger of EMTs. A number of transcription factors are EMT inducers by direct transcriptional repression of CDH1, such as the basic helix-loop-helix factors (E12/E47 and Twist), the zincfinger proteins (Snail, and Slug) and Competing interests: none declared. Conflict of interests: none declared.
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Pyk2 expression was inversely related to that of E-cadherin, and Pyk2-deficiency prevented TGF-β from stimulating the growth of breast cancer cells, indicating that Pyk2 mediates distinct elements of the EMT programme and metastatic cascade regulated by TGF-β, particularly the initiation of secondary tumour outgrowth by disseminated cells 24 . In different subtypes of breast cancer, the signalling pathways involved in TGF-β-mediated EMT are not exactly the same. Recently, research showed that upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells 25 . Significant cross-talk exists between TGF-β and other signalling pathways, such as Notch, Wnt, NF-кB and RTKs, to induce EMT and promote invasive phenotype of breast cancer cells, such as Six1, which can activate both TGF-β and Wnt signalling.
Notch and Wnt signalling pathways
Notch and Wnt signalling pathways play essential roles in development and maintenance of organs and tissues, involved in cell proliferation, survival, apoptosis and differentiation, as well as stem cell self-renewal. And it is believed that Notch and Wnt signalling pathways may play an important role in the induction of EMT and the sequent progression of breast carcinomas.
Mammals express four transmembrane Notch receptors (Notch1/2/3/4) and five canonical transmembrane ligands (Jagged-1/2 and Deltalike-1/3/4). Cell-cell contact is generally necessary for activation of Notch signalling, through ligand-receptor binding and proteolytic cleavage sequence and release of Notch intracellular domain, which translocates to the nucleus to activate Notch target genes, including Myc, p21, HES and HES-related repressor families (HERP, HRT and HEY) 26 . Slug was reported to be essential for Notchmediated repression of E-cadherin, cancer cells, accompanied with AKT/ ERK1/2 inactivation and reversing the EMT and CSC phenotype 17 . It is reported that re-expression of miR-375, targeting metadherin, was sufficient to sensitise tamoxifen-resistant breast cancer cells to tamoxifen and partly reversed EMT 18 . Six1 activates the tumour promotional arm of transforming growth factor-β (TGF-β) signalling, via upregulating the miR-106b-25 miRNA cluster, and the miR-106b-25 cluster is sufficient to induce an EMT and a tumour-initiating cell phenotype 19 .
Transforming growth factor-β signalling pathway TGF-β, a cytokine produced by mesenchymal stromal and inflammatory cells, regulates cell proliferation, cell differentiation, apoptosis and matrix accumulation, and is probably implicated as the primary inducer of EMT. It is now generally accepted that TGF-β signalling plays a dual role in tumour carcinogenesis and metastasis. Although during the early stages of carcinogenesis, TGF-β acts as a tumour suppressor, via upregulating cyclin-dependent kinase (CDK) inhibitors (p15 and p21) and shut-down expression of their repressor Myc 20 , it promotes metastasis through facilitating induction of EMT at advanced stages of carcinogenesis 21 . TGF-β, binding to type I/II serine-threonine kinase receptors, regulates transcription by Smad-dependent/independent TGF-β-receptor signalling pathways. And both Smad-dependent/independent pathways overlap and collaborate to regulate the transcription of EMT regulators, including Snail, Slug and Twist
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. TGF-β signalling downregulates expression of E-cadherin, via Snail1/2, HMGA2 and ZEB1/2. CDK5 is commonly overexpressed and significantly correlated with several poor prognostic parameters of breast cancer, and essential for TGF-β1-induced EMT and breast cancer progression 23 . resulted in the inhibition of cell migration, invasion and metastasis of basal-like breast cancer 11 . Twist, regulated by Wnt/betacatenin signalling, is highly expressed in breast cancer tissues, playing important roles in mammary tumourigenesis, with the reverse E-cadherin expression 12 . Stable overexpression of Twist in the breast cancer cell line, MCF-7, induced its morphology to a fibroblastic-like phenotype, which exhibited protein markers representative of a mesenchymal transformation, and resulted in angiogenesis through upregulating vascular endothelial growth factor 13 . An autocrine MAPK intracellular signalling pathway, activated by OPN extracellular binding to MB231, resulted in Twist activation and promoted Bmi1 expression, and further EMT initiation and cellular migration Competing interests: none declared. Conflict of interests: none declared.
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differentiation by directly repressing the transcription of ZEB1/2, and leading de-repression of CDH1 and eliciting EMT, and is downregulated in the claudin-low subtype of breast cancer with gene expression signatures for both EMT and CSC
39
. miR200s also target Bmi1, which is a positive regulator in self-renewal of CSCs and breast cancer metastases 40 . Interestingly, the EMT-resulting mesenchymal tumour cell had a CD44 high /CD24 low phenotype with the ability to re-establish an epithelial tumour and increased drug resistance, consistent with breast CSCs signatures 41 . Many patients with breast cancers ultimately relapse due to the presence of residual cancer cells that are presumably treatment resistant. Examination of breast tumours after neo-adjuvant chemotherapy revealed an increase in the CSC-enriched CD44 
Conclusion
Breast carcinoma is a heterogeneous group of neoplasms, with a high degree of diversity of gene expression profiling between and within tumours, representing a variety of activates Wnt/β-catenin pathway that leads to transcription of EGF4 and promotes EMT-like transition 33 . . TGF-β increases Notch activity through Smad3, which upregulates both Jagged-1 and Hey-1, and subsequently promotes Slug expression, resulting in suppressing E-cadherin 27 . And TGF-β-induced EMT can be blocked by knockdown of Hey-1 or Jagged-1 or by pharmacological inactivation of Notch 28 . Bone is hypoxic and one of the most frequently targeted organs for breast cancer metastasis, and Jagged-2 is upregulated in bone marrow stroma under hypoxia, which significantly promotes EMT and selfrenewal of breast CSCs 29 , indicating a vital role of Notch-induced EMT in tumour progression and metastasis. And hypoxia-induced downregulation of miR-34a can promote EMT by directly targeting the Notch1 and Jagged-1, and subsequently, Notch downstream signalling in tubular epithelial cells 30 . β-catenin, one of the downstream signalling molecules of the Wnt signalling pathway, can enhance cellcell adhesion when bound to cadherin complexes in adherens junctions. In the absence of Wnt, cytoplasmic β-catenin is phosphorylated by the destruction complex, consisting of axin, adenomatous polyposis coli, glycogen synthase kinase-3β (GSK-3β) and casein kinase, recognised by E3 ubiquitin ligase β-Trcp for proteasomal degradation. In the presence of Wnt ligands, GSK-3β is inactivated, and β-catenin is stabilised, resulting in translocation into the nucleus and regulates the transcription of Wnt target genes, such as Snail and Slug 31 . Snail can functionally interact with β-catenin to enhance the activation of Wnt signalling, which establishes a positive feedback loop to Wnt-dependent transcription. It is reported that repression of Wnt/β-catenin signalling can prevent EMT and sequent metastasis of basal-like breast cancer to the lungs 32 . In trastuzumab-resistant HER2-overexpressing breast cancer cells, expression of Wnt3 histopathological features, genetic markers, risk of disease progression, prognostic outcomes and therapeutic resistance. Conventional treatment for breast cancers mainly targets the differentiated tumour cells; however, cancer cells in a significant amount of patients can acquire chemotherapy resistance after standard therapies, resulting in relapse or metastasis with poor prognosis. The link between EMT and CSCs is widely accepted that a minor population of tumour cells, with EMT and CSCs traits, may respond for tumour metastasis and recurrence. Therefore, it is challenging to probe and uncover the mechanistic regulation of oncogenic EMT, which will contribute to our understanding of metastatic dissemination and the role of targeting EMT with existing therapy as well as developing new drugs, in order to prevent metastasis and to diminish distant recurrence in patients with breast cancers.
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